Hepatic enzyme induction patterns and phenothiazine side effects.

Area of Science:

• Pharmacology
• Neuroscience
• Biochemistry

Background:

• Phenothiazines are antipsychotic drugs used to treat psychosis.
• Neurological side effects are common with phenothiazine treatment.
• Individual variability in drug response and side effects is a significant clinical challenge.

Purpose of the Study:

• To investigate the relationship between D-glucaric acid excretion and phenothiazine treatment in psychotic patients.
• To determine if changes in D-glucaric acid excretion correlate with the incidence and severity of neurological side effects.
• To explore the role of enzyme induction in phenothiazine metabolism and its clinical implications.

Main Methods:

• Measurement of urinary D-glucaric acid excretion in psychotic patients undergoing phenothiazine treatment for 12 days.
• Comparison of D-glucaric acid levels between patients and a control group without psychiatric illness.
• Assessment of neurological side effects in relation to D-glucaric acid excretion levels.

Main Results:

• Approximately 50% of psychotic patients exhibited a rise in D-glucaric acid excretion during phenothiazine treatment, indicative of enzyme induction.
• Patients with increased D-glucaric acid excretion reported fewer and less severe neurological side effects.
• A significant correlation was observed between higher D-glucaric acid levels and reduced neurological adverse events.

Conclusions:

• Individual differences in phenothiazine metabolism, suggested by varying D-glucaric acid excretion, may explain differential clinical responses.
• Enzyme induction, as indicated by D-glucaric acid levels, appears to be a protective factor against phenothiazine-induced neurological side effects.
• Monitoring D-glucaric acid excretion could offer insights into predicting and managing phenothiazine treatment outcomes.